-
Mashup Score: 1Durvalumab After Chemoradiotherapy in Unresectable NSCLC: Real-World Use and Outcomes - 14 day(s) ago
In a retrospective cohort study (SPOTLIGHT), investigators found that a substantial proportion of patients with unresectable stage III NSCLC did not receive consolidation durvalumab after chemoradioth…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
The phase III CONTACT-01 trial evaluated atezolizumab plus cabozantinib vs docetaxel in patients with metastatic NSCLC after they had received checkpoint inhibitor treatment and chemotherapy.
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
In patients with resectable non–small cell lung cancer (NSCLC), perioperative treatment with the checkpoint inhibitor tislelizumab plus platinum-doublet chemotherapy led to a statistically significant benefit in event-free survival and a favorable trend for overall survival, investigators for the phase III RATIONALE-315 reported at the February 2024 European Society for Medical Oncology (ESMO) Virtual Plenary (Abstract VP1- 2024). “Major pathologic and complete pathologic responses were also significantly
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Durvalumab Plus Ceralasertib in Patients With Immunotherapy-Resistant NSCLC - The ASCO Post - 3 month(s) ago
“Patients with advanced [NSCLC] face significant challenges when standard-of-care treatments fail,” stressed senior study author John Heymach, MD, PhD, Chair of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. “For these [patients], options become limited, emphasizing the urgent need for innovative approaches,” he added. In the phase II umbrella HUDSON study, researchers assigned 268 patients with advanced NSCLC whose tumors progressed following standard therapy
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Addition of Nivolumab to Chemotherapy in EGFR-Mutant Metastatic NSCLC After Disease Progression on Prior Therapy - The ASCO Post - 4 month(s) ago
As reported in the Journal of Clinical Oncology by Tony Mok, MD, FRCPC, FASCO, and colleagues, final results of the primarily Asian phase III CheckMate 722 trial showed no progression-free survival benefit with the addition of nivolumab to chemotherapy in pat ients with EGFR -mutant metastatic non–small cell lung cancer (NSCLC) after disease progression on EGFR tyrosine kinase inhibitors. In the open-label trial, 294 patients from sites in nine countries were randomly assigned between March 2017 and June
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2PAPILLON: Adding Amivantamab to First-Line Chemotherapy Prolongs Progression-Free Survival in NSCLC Subset - The ASCO Post - 5 month(s) ago
In the phase III PAPILLON trial, the addition of the bispecific antibody amivantamab-vmjw to chemotherapy resulted in a near doubling in median progression-free survival vs chemotherapy alone in patients with untreated non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertions. The primary results were presented during the Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2023 by Nicolas Girard, MD, of the Curie Institute, Paris. 1
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC - The ASCO Post - 6 month(s) ago
In the phase II SPRINT trial reported in the Journal of Clinical Oncology, Ohri et al found that a chemotherapy-sparing regimen of pembrolizumab with risk-adapted radiotherapy was associated with good outcomes in patients with stage III or unresectable stage II non–small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) of ≥ 50%. In the study, 25 patients were enrolled from three U.S. centers between August 2018 and November 2021. Patents received three cycles of induction pembrolizumab
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Durvalumab May Offer Survival Benefit in Patients With NSCLC and Borderline Performance Status - The ASCO Post - 6 month(s) ago
Lung cancer is the deadliest can cer type, causing over 125,000 deaths in the United States per year. When NSCLC, which makes up about 85% of all lung cancer cases, progresses to the advanced or metastatic stage, the rate of survival decreases. “Over the last decade, the development of immunotherapies has revolutionized treatment for NSCLC and greatly improved survival outcomes,” explained senior study author Liza Villaruz, MD, Associate Professor of Medicine at the University of Pittsburgh and Co-Leader
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
By Matthew Stenger Posted: 11/2/2023 11:18:00 AM Last Updated: 11/2/2023 12:48:36 PM As reported in The New England Journal of Medicine by John V. Heymach, MD, PhD, and colleagues, the phase III AEGEAN trial has shown that perioperative durvalumab improved event-free survival and pathologic complete response…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Durvalumab After Chemoradiotherapy in Unresectable NSCLC: Real-World Use and Outcomes https://t.co/ZwKSGMwT8F #LCSM #lungcancer #oncology #immunotherapy